This week’s episode will be focusing on an update of a late-breaking abstract presented at ASH 2025 this past week: the Phase 3 BRUIN-CLL 313 trial looking at Pirtobrutinib vs Bendamustine/Rituximab in 1L Chronic Lymphocytic Leukemia (CLL).
All content for Two Onc Docs is the property of Sam and Karine and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This week’s episode will be focusing on an update of a late-breaking abstract presented at ASH 2025 this past week: the Phase 3 BRUIN-CLL 313 trial looking at Pirtobrutinib vs Bendamustine/Rituximab in 1L Chronic Lymphocytic Leukemia (CLL).
This week’s episode will be focusing on Gastric Adenocarcinoma. We will go over all the important details on risk factors, diagnostic work-up, staging and treatment for both local regional disease and metastatic disease with updates in 2025 since we last covered this topic in 2023.
Two Onc Docs
This week’s episode will be focusing on an update of a late-breaking abstract presented at ASH 2025 this past week: the Phase 3 BRUIN-CLL 313 trial looking at Pirtobrutinib vs Bendamustine/Rituximab in 1L Chronic Lymphocytic Leukemia (CLL).
